Drug intelligence / Profile preview

IMARK S

Development stage: Preclinical
Lead developer: Nissui Corporation
Modality: Small Molecules
Administration: Oral

Overview

IMARK S is a commercially available omega-3 emulsified formulation developed by Nippon Suisan Kaisha, Ltd. It contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are omega-3 fatty acids. It is being investigated for its safety and efficacy in maintaining remission in patients with Crohn's disease. The formulation is designed for efficient intestinal absorption and exerts anti-inflammatory effects by modulating eicosanoid synthesis, leading to the formation of anti-inflammatory prostanoids and leukotrienes.

Brand names: IMARK S®

Beyond the preview

Go deeper on IMARK S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMARK S.

Explore the full profile